Charles River Laboratories ROE 2010-2024 | CRL

Current and historical return on equity (ROE) values for Charles River Laboratories (CRL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Charles River Laboratories ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-09-30 $0.42B $3.79B 11.46%
2024-06-30 $0.44B $3.73B 12.35%
2024-03-31 $0.44B $3.65B 12.85%
2023-12-31 $0.47B $3.60B 14.27%
2023-09-30 $0.47B $3.31B 14.97%
2023-06-30 $0.48B $3.26B 16.12%
2023-03-31 $0.50B $3.11B 17.40%
2022-12-31 $0.49B $2.98B 17.83%
2022-09-30 $0.44B $2.63B 16.70%
2022-06-30 $0.44B $2.65B 17.31%
2022-03-31 $0.42B $2.62B 17.04%
2021-12-31 $0.39B $2.54B 16.49%
2021-09-30 $0.40B $2.43B 17.48%
2021-06-30 $0.40B $2.32B 18.57%
2021-03-31 $0.38B $2.19B 18.83%
2020-12-31 $0.36B $2.12B 19.59%
2020-09-30 $0.30B $1.90B 17.32%
2020-06-30 $0.27B $1.76B 16.46%
2020-03-31 $0.25B $1.66B 15.78%
2019-12-31 $0.25B $1.64B 16.71%
2019-09-30 $0.23B $1.54B 16.24%
2019-06-30 $0.22B $1.46B 16.11%
2019-03-31 $0.23B $1.40B 17.74%
2018-12-31 $0.23B $1.32B 18.51%
2018-09-30 $0.14B $1.26B 11.83%
2018-06-30 $0.13B $1.19B 11.73%
2018-03-31 $0.13B $1.14B 12.34%
2017-12-31 $0.12B $1.05B 12.56%
2017-09-30 $0.20B $1.03B 21.35%
2017-06-30 $0.18B $0.97B 20.69%
2017-03-31 $0.17B $0.88B 19.26%
2016-12-31 $0.16B $0.84B 18.61%
2016-09-30 $0.14B $0.87B 17.58%
2016-06-30 $0.14B $0.84B 18.39%
2016-03-31 $0.16B $0.78B 21.11%
2015-12-31 $0.15B $0.74B 21.27%
2015-09-30 $0.15B $0.71B 21.02%
2015-06-30 $0.14B $0.71B 20.56%
2015-03-31 $0.13B $0.67B 18.72%
2014-12-31 $0.13B $0.68B 18.50%
2014-09-30 $0.12B $0.67B 17.53%
2014-06-30 $0.12B $0.68B 17.48%
2014-03-31 $0.11B $0.70B 16.43%
2013-12-31 $0.10B $0.64B 15.94%
2013-09-30 $0.10B $0.66B 16.04%
2013-06-30 $0.09B $0.65B 14.97%
2013-03-31 $0.10B $0.63B 16.01%
2012-12-31 $0.10B $0.60B 16.53%
2012-09-30 $0.11B $0.60B 18.69%
2012-06-30 $0.10B $0.57B 18.65%
2012-03-31 $0.10B $0.56B 18.79%
2011-12-31 $0.11B $0.53B 19.61%
2011-09-30 $-0.26B $0.54B -43.94%
2011-06-30 $-0.31B $0.59B -42.47%
2011-03-31 $-0.32B $0.56B -35.17%
2010-12-31 $-0.34B $0.69B -30.01%
2010-09-30 $0.02B $1.04B 1.85%
2010-06-30 $0.09B $1.39B 6.25%
2010-03-31 $0.11B $1.38B 7.87%
2009-12-31 $0.11B $1.37B 8.73%
Sector Industry Market Cap Revenue
Medical Medical Services $9.516B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $91.424B 11.34
Cencora (COR) United States $47.484B 17.51
DiDi Global (DIDIY) China $23.330B 0.00
Natera (NTRA) United States $21.401B 0.00
ICON (ICLR) Ireland $16.136B 14.37
Viatris (VTRS) United States $15.576B 4.80
Avantor (AVTR) United States $13.422B 20.12
Revvity (RVTY) United States $13.376B 23.24
CochLear (CHEOY) Australia $12.844B 0.00
BioMerieux (BMXMF) France $12.666B 0.00
Solventum (SOLV) United States $11.583B 0.00
Medpace Holdings (MEDP) United States $9.789B 27.58
Doximity (DOCS) United States $9.620B 56.63
HealthEquity (HQY) United States $8.966B 48.66
Sonic Healthcare (SKHHY) Australia $8.758B 0.00
Bausch + Lomb (BLCO) Canada $6.885B 32.05
Life Times (LTH) United States $5.085B 33.66
Sotera Health (SHC) United States $3.855B 20.62
Organon (OGN) United States $3.757B 3.79
BrightSpring Health Services (BTSG) United States $3.247B 69.07
Surgery Partners (SGRY) United States $2.892B 32.97
PACS (PACS) United States $2.606B 0.00
Concentras Parent (CON) United States $2.581B 0.00
Ardent Health Partners (ARDT) United States $2.375B 0.00
Premier (PINC) United States $2.143B 11.15
Alignment Healthcare (ALHC) United States $2.126B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GeneDx Holdings (WGS) United States $1.952B 0.00
GoodRx Holdings (GDRX) United States $1.616B 42.40
Teladoc Health (TDOC) United States $1.537B 0.00
Pediatrix Medical (MD) United States $1.255B 12.28
CareDx (CDNA) United States $1.183B 0.00
Progyny (PGNY) United States $1.164B 23.57
Establishment Labs Holdings (ESTA) $1.050B 0.00
AMN Healthcare Services Inc (AMN) United States $0.954B 6.46
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Embecta (EMBC) United States $0.778B 5.18
SBC Medicals (SBC) United States $0.677B 0.00
Agilon Health (AGL) United States $0.655B 0.00
InnovAge Holding (INNV) United States $0.647B 0.00
Auna S.A (AUNA) Luxembourg $0.536B 0.00
Sonida Senior Living (SNDA) United States $0.425B 0.00
DocGo (DCGO) United States $0.410B 15.46
Enhabit (EHAB) United States $0.366B 31.61
COMPASS Pathways (CMPS) United Kingdom $0.326B 0.00
LifeMD (LFMD) United States $0.241B 0.00
ModivCare (MODV) United States $0.223B 12.09
Sera Prognostics (SERA) United States $0.209B 0.00
Beauty Health (SKIN) United States $0.200B 0.00
Biodesix (BDSX) United States $0.180B 0.00
Nutex Health (NUTX) United States $0.156B 0.00
Ascend Wellness Holdings (AAWH) United States $0.100B 0.00
So-Young (SY) China $0.092B 22.25
MultiPlan (MPLN) United States $0.084B 0.00
Singular Genomics Systems (OMIC) United States $0.054B 0.00
OncoCyte (OCX) United States $0.043B 0.00
NeueHealth (NEUE) United States $0.041B 1.08
Co-Diagnostics (CODX) United States $0.034B 0.00
Pheton Holdings (PTHL) China $0.030B 0.00
IceCure Medical (ICCM) Israel $0.028B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.020B 0.00
Oncology Institute (TOI) United States $0.014B 0.00
SeaStar Medical Holding (ICU) United States $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
Intelligent Bio Solutions (INBS) United States $0.006B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00